| Value | ₹4.17 Cr |
|---|
BSE filing, NSE: SHUKRAPHAR. Summary written from the filing by ALFA Finder's alert engine.
Shukra Pharmaceuticals Ltd: key numbers
- Share price
- ₹71.89
- Market cap
- ₹3,181 Cr
- Revenue (annual)
- ₹56.73 Cr
- Net profit (annual)
- ₹22.06 Cr
- P/E (TTM)
- 93.6×Sector 46.1×
- Promoter holding
- 51.15%+0.19% QoQ
- FII holding
- 0.43%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shukra Pharmaceuticals Ltd
All →Shukra Pharmaceuticals Board Meeting Date
Shukra Medtech Limited has scheduled a board meeting on November 3, 2026, to consider and approve its unaudited financial results for the quarter ended September 2026.
Shukra Pharmaceuticals Other Announcement
Shukra Medtech submitted a revised CA certificate to NSE for its name and symbol change application. The filing requests final exchange approval for the corporate rename.
Shukra Pharmaceuticals Other Announcement
Shukra Pharmaceuticals Limited has submitted the certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Shukra Pharmaceuticals Capital Structure Change
Shukra Pharmaceuticals allotted 17.35 lakh equity shares upon warrant conversion to promoters. The exercise raised Rs. 4.63 Crore, increasing the paid-up capital.
- Value
- ₹4.63 Cr
Shukra Pharmaceuticals Price Movement Clarification
Shukra Pharmaceuticals clarified that the recent share price movement is market-driven. The company confirmed no undisclosed, price-sensitive information exists.
Shukra Pharmaceuticals Annual General Meeting
Shukra Pharmaceuticals Ltd issued a corrigendum to its Postal Ballot notice regarding the proposed alteration of its Main Object Clause and name change.
Other debt & borrowing announcements
All →Poonawalla Fincorp Debt & Borrowing: ₹1,318 Cr
Poonawalla Fincorp allotted Rs 1,318 Crore NCDs across two series G1 and G2. The allotment comprises zero-coupon and 9% coupon debentures maturing by 2030.
- Value
- ₹1,318 Cr
Fusion Finance Debt & Borrowing: ₹1.35 Cr
Fusion Finance Limited paid Rs.1.35 Crore monthly interest on its non-convertible debentures on 28 October 2026. The payment was made on time, one day ahead of the stated due date of 29 October 2026.
- Value
- ₹1.35 Cr
Bajaj Finance Debt & Borrowing: ₹300 Cr
Bajaj Life Insurance purchased 30,000 NCDs of Bajaj Finance worth ₹300 Crore on NSE. The open-market debt buy signals promoter confidence in the company.
- Value
- ₹300.0 Cr
Fusion CX Debt & Borrowing: ₹21.85 Cr
Fusion CX lent up to Rs.21.85 Crore (USD 2.3 million) to wholly owned subsidiary Fusion BPO Services. Terms: 8.5% interest, three-year tenure, unsecured.
- Value
- ₹21.85 Cr
- Execution
- 3 years from the date of disbursal
Fusion CX Debt & Borrowing
Fusion CX Limited executed an unsecured inter-corporate term loan at 8.5% p.a. for three years with its wholly owned subsidiary Fusion BPO Services Ltd, a related party. Amount is not stated in the filing.
- Execution
- 3 years from the date of disbursal
Spandana Sphoorty Financial Debt & Borrowing: ₹0.49 Cr
Spandana paid ₹0.49 Crore of quarterly interest on its secured NCDs on 27 October 2026. The coupon rate is 10.75% on a ₹50 Crore issue.
- Value
- ₹0.49 Cr